Immunogenicity and immune memory after a pneumococcal polysaccharide vaccine booster in a high-risk population primed with 10-valent or 13-valent pneumococcal conjugate vaccine: A randomized controlled trial in Papua New Guinean children

Anita H.J. van den Biggelaar, William S. Pomat, Geraldine Masiria, Sandra Wana, Birunu Nivio, Jacinta Francis, Rebecca Ford, Megan Passey, Lea Ann Kirkham, Peter Jacoby, Deborah Lehmann, Peter Richmond

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We investigated the immunogenicity, seroprotection rates and persistence of immune memory in young children at high risk of pneumococcal disease in Papua New Guinea (PNG). Children were primed with 10-valent (PCV10) or 13-valent pneumococcal conjugate vaccines (PCV13) at 1, 2 and 3 months of age and randomized at 9 months to receive PPV (PCV10/PPV-vaccinated, n = 51; PCV13/PPV-vaccinated, n = 52) or no PPV (PCV10/PPV-naive, n = 57; PCV13/PPV-naive, n = 48). All children received a micro-dose of PPV at 23 months of age to study the capacity to respond to a pneumococcal challenge. PPV vaccination resulted in significantly increased IgG responses (1.4 to 10.5-fold change) at 10 months of age for all PPV-serotypes tested. Both PPV-vaccinated and PPV-naive children responded to the 23-month challenge and post-challenge seroprotection rates (IgG ≥ 0.35 µg/mL) were similar in the two groups (80–100% for 12 of 14 tested vaccine serotypes). These findings show that PPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses. Priming with currently available PCVs followed by a PPV booster in later infancy could offer improved protection to young children at high risk of severe pneumococcal infections caused by a broad range of serotypes.

Original languageEnglish
Article number17
JournalVaccines
Volume7
Issue number1
DOIs
Publication statusPublished - 4 Feb 2019

Fingerprint

Conjugate Vaccines
Pneumococcal Vaccines
Randomized Controlled Trials
Population
Pneumococcal Infections
Immunoglobulin G
Papua New Guinea
13-valent pneumococcal vaccine
Vaccination
Vaccines
Serogroup
10-valent pneumococcal conjugate vaccine

Cite this

@article{933e8d2cb9ed46878867ca578acde55d,
title = "Immunogenicity and immune memory after a pneumococcal polysaccharide vaccine booster in a high-risk population primed with 10-valent or 13-valent pneumococcal conjugate vaccine: A randomized controlled trial in Papua New Guinean children",
abstract = "We investigated the immunogenicity, seroprotection rates and persistence of immune memory in young children at high risk of pneumococcal disease in Papua New Guinea (PNG). Children were primed with 10-valent (PCV10) or 13-valent pneumococcal conjugate vaccines (PCV13) at 1, 2 and 3 months of age and randomized at 9 months to receive PPV (PCV10/PPV-vaccinated, n = 51; PCV13/PPV-vaccinated, n = 52) or no PPV (PCV10/PPV-naive, n = 57; PCV13/PPV-naive, n = 48). All children received a micro-dose of PPV at 23 months of age to study the capacity to respond to a pneumococcal challenge. PPV vaccination resulted in significantly increased IgG responses (1.4 to 10.5-fold change) at 10 months of age for all PPV-serotypes tested. Both PPV-vaccinated and PPV-naive children responded to the 23-month challenge and post-challenge seroprotection rates (IgG ≥ 0.35 µg/mL) were similar in the two groups (80–100{\%} for 12 of 14 tested vaccine serotypes). These findings show that PPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses. Priming with currently available PCVs followed by a PPV booster in later infancy could offer improved protection to young children at high risk of severe pneumococcal infections caused by a broad range of serotypes.",
keywords = "Antibodies, Immune memory, Papua New Guinea, Pneumococcal conjugate vaccine, Pneumococcal polysaccharide vaccine, S. pneumoniae",
author = "{van den Biggelaar}, {Anita H.J.} and Pomat, {William S.} and Geraldine Masiria and Sandra Wana and Birunu Nivio and Jacinta Francis and Rebecca Ford and Megan Passey and Kirkham, {Lea Ann} and Peter Jacoby and Deborah Lehmann and Peter Richmond",
year = "2019",
month = "2",
day = "4",
doi = "10.3390/vaccines7010017",
language = "English",
volume = "7",
journal = "Vaccines",
issn = "2076-393X",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

Immunogenicity and immune memory after a pneumococcal polysaccharide vaccine booster in a high-risk population primed with 10-valent or 13-valent pneumococcal conjugate vaccine : A randomized controlled trial in Papua New Guinean children. / van den Biggelaar, Anita H.J.; Pomat, William S.; Masiria, Geraldine; Wana, Sandra; Nivio, Birunu; Francis, Jacinta; Ford, Rebecca; Passey, Megan; Kirkham, Lea Ann; Jacoby, Peter; Lehmann, Deborah; Richmond, Peter.

In: Vaccines, Vol. 7, No. 1, 17, 04.02.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Immunogenicity and immune memory after a pneumococcal polysaccharide vaccine booster in a high-risk population primed with 10-valent or 13-valent pneumococcal conjugate vaccine

T2 - A randomized controlled trial in Papua New Guinean children

AU - van den Biggelaar, Anita H.J.

AU - Pomat, William S.

AU - Masiria, Geraldine

AU - Wana, Sandra

AU - Nivio, Birunu

AU - Francis, Jacinta

AU - Ford, Rebecca

AU - Passey, Megan

AU - Kirkham, Lea Ann

AU - Jacoby, Peter

AU - Lehmann, Deborah

AU - Richmond, Peter

PY - 2019/2/4

Y1 - 2019/2/4

N2 - We investigated the immunogenicity, seroprotection rates and persistence of immune memory in young children at high risk of pneumococcal disease in Papua New Guinea (PNG). Children were primed with 10-valent (PCV10) or 13-valent pneumococcal conjugate vaccines (PCV13) at 1, 2 and 3 months of age and randomized at 9 months to receive PPV (PCV10/PPV-vaccinated, n = 51; PCV13/PPV-vaccinated, n = 52) or no PPV (PCV10/PPV-naive, n = 57; PCV13/PPV-naive, n = 48). All children received a micro-dose of PPV at 23 months of age to study the capacity to respond to a pneumococcal challenge. PPV vaccination resulted in significantly increased IgG responses (1.4 to 10.5-fold change) at 10 months of age for all PPV-serotypes tested. Both PPV-vaccinated and PPV-naive children responded to the 23-month challenge and post-challenge seroprotection rates (IgG ≥ 0.35 µg/mL) were similar in the two groups (80–100% for 12 of 14 tested vaccine serotypes). These findings show that PPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses. Priming with currently available PCVs followed by a PPV booster in later infancy could offer improved protection to young children at high risk of severe pneumococcal infections caused by a broad range of serotypes.

AB - We investigated the immunogenicity, seroprotection rates and persistence of immune memory in young children at high risk of pneumococcal disease in Papua New Guinea (PNG). Children were primed with 10-valent (PCV10) or 13-valent pneumococcal conjugate vaccines (PCV13) at 1, 2 and 3 months of age and randomized at 9 months to receive PPV (PCV10/PPV-vaccinated, n = 51; PCV13/PPV-vaccinated, n = 52) or no PPV (PCV10/PPV-naive, n = 57; PCV13/PPV-naive, n = 48). All children received a micro-dose of PPV at 23 months of age to study the capacity to respond to a pneumococcal challenge. PPV vaccination resulted in significantly increased IgG responses (1.4 to 10.5-fold change) at 10 months of age for all PPV-serotypes tested. Both PPV-vaccinated and PPV-naive children responded to the 23-month challenge and post-challenge seroprotection rates (IgG ≥ 0.35 µg/mL) were similar in the two groups (80–100% for 12 of 14 tested vaccine serotypes). These findings show that PPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses. Priming with currently available PCVs followed by a PPV booster in later infancy could offer improved protection to young children at high risk of severe pneumococcal infections caused by a broad range of serotypes.

KW - Antibodies

KW - Immune memory

KW - Papua New Guinea

KW - Pneumococcal conjugate vaccine

KW - Pneumococcal polysaccharide vaccine

KW - S. pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=85062272081&partnerID=8YFLogxK

U2 - 10.3390/vaccines7010017

DO - 10.3390/vaccines7010017

M3 - Article

VL - 7

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 1

M1 - 17

ER -